--- title: "Quest Diagnostics Incorporated (NYSE:DGX) Plans Quarterly Dividend of $0.86" type: "News" locale: "en" url: "https://longbridge.com/en/news/295793111.md" description: "Quest Diagnostics (NYSE: DGX) announced a quarterly dividend of $0.86 per share. Shareholders of record on October 6, 2024, will receive the payment on October 21, 2024. The ex-dividend date is also October 6. This represents an annualized dividend yield of 1.4%. Quest Diagnostics has increased its dividend annually for the past 14 years." datetime: "2026-08-13T11:50:27.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295793111.md) - [en](https://longbridge.com/en/news/295793111.md) - [zh-HK](https://longbridge.com/zh-HK/news/295793111.md) --- # Quest Diagnostics Incorporated (NYSE:DGX) Plans Quarterly Dividend of $0.86 **Quest Diagnostics Incorporated** (NYSE:DGX - Get Free Report) announced a quarterly dividend on Wednesday, August 12th. Stockholders of record on Tuesday, October 6th will be given a dividend of 0.86 per share by the medical research company on Wednesday, October 21st. This represents a c) annualized dividend and a dividend yield of 1.4%. The ex-dividend date of this dividend is Tuesday, October 6th. Get **Quest Diagnostics** alerts: - Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests Quest Diagnostics has raised its dividend by an average of 0.1%annually over the last three years and has increased its dividend every year for the last 14 years. Quest Diagnostics has a payout ratio of 32.7% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Quest Diagnostics to earn $11.95 per share next year, which means the company should continue to be able to cover its $3.44 annual dividend with an expected future payout ratio of 28.8%. ## Quest Diagnostics Stock Up 0.0% Shares of DGX opened at $237.53 on Thursday. The firm has a market capitalization of $26.22 billion, a P/E ratio of 25.22, a P/E/G ratio of 2.19 and a beta of 0.56. Quest Diagnostics has a 12-month low of $171.18 and a 12-month high of $240.13. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.72. The firm has a fifty day moving average price of $214.12 and a 200-day moving average price of $202.57. - LifeMD Shares Come Back to Life on GLP-1 Business Growth Quest Diagnostics (NYSE:DGX - Get Free Report) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $3.12 EPS for the quarter, topping the consensus estimate of $2.82 by $0.30. Quest Diagnostics had a net margin of 9.18% and a return on equity of 16.01%. The company had revenue of $3.04 billion for the quarter, compared to the consensus estimate of $2.97 billion. During the same quarter last year, the firm posted $2.62 EPS. The firm's revenue was up 10.2% compared to the same quarter last year. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. Equities research analysts expect that Quest Diagnostics will post 11.15 earnings per share for the current year. ## About Quest Diagnostics (Get Free Report) Quest Diagnostics NYSE: DGX is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening. - Exact Sciences Serves Investors Exactly What They Wished For Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology. ## Read More - Five stocks we like better than Quest Diagnostics - Franco-Nevada Earnings: Gold Is Rallying, But Does the Stock Even Care? - GE Vernova’s AI Power Boom Faces a Profit Test - Cardinal Health Earnings: Can Perfection Get Priced In Twice? - Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._ Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Add As Preferred Source ## Should You Invest $1,000 in Quest Diagnostics Right Now? Before you consider Quest Diagnostics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Quest Diagnostics wasn't on the list. While Quest Diagnostics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [DGX.US](https://longbridge.com/en/quote/DGX.US.md) - [MYGN.US](https://longbridge.com/en/quote/MYGN.US.md) - [LFMD.US](https://longbridge.com/en/quote/LFMD.US.md) - [EXAS.US](https://longbridge.com/en/quote/EXAS.US.md) - [FNV.US](https://longbridge.com/en/quote/FNV.US.md) - [GEV.US](https://longbridge.com/en/quote/GEV.US.md) - [CAH.US](https://longbridge.com/en/quote/CAH.US.md) - [NBIS.US](https://longbridge.com/en/quote/NBIS.US.md) - [LFMDP.US](https://longbridge.com/en/quote/LFMDP.US.md) ## Related News & Research - [Quest Diagnostics declares quarterly cash dividend of $0.86 per share](https://longbridge.com/en/news/295705037.md) - [Quest Diagnostics sets BRL 1.5-per-unit distribution for Oct. 27 payment](https://longbridge.com/en/news/295830247.md) - [Cboe Global Markets raises dividend by 19% to $0.86](https://longbridge.com/en/news/295882814.md) - [Resources Connection declares $0.07 dividend](https://longbridge.com/en/news/295612769.md) - [Genuine Parts declares $1.062 dividend](https://longbridge.com/en/news/295579964.md)